UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

Reuben Benjamin, Victoria Potter, Marcela V. Maus et al.|The Lancet Haematology|2022

Cited by 139